Studying caspofungin dosing in very ill children
Part of Infections clinical trials.
This study looks at how caspofungin works in children who are very sick and in the pediatric intensive care unit. It helps doctors better choose dosing to keep the medicine at the right level.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is currently receiving caspofungin in the pediatric ICU
- A parent or legal guardian can sign the informed consent form
- Your child is not already enrolled in another clinical trial
- Study staff can review your child’s current care and medicine use
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether giving common antibiotics in certain dose schedules (either through a drip over time or continuously) is done in a way that fits pediatric intensive care needs. It may help improve antibiotic treatment for children who are very sick and need antibiotics.
This study looks at how much posaconazole stays in your body while you receive it to prevent fungal infections during chemotherapy or after a stem cell transplant. Your care team will use standard posaconazole treatment and may take extra blood samples to understand its levels.
This trial enrolls children in the pediatric intensive care unit (PICU) who have a severe infection. It aims to better understand germs and drug resistance so future treatments can be more effective.
This trial measures how ceftazidime (an antibiotic) moves through the body and how it works in children with severe infections in the pediatric intensive care unit. It may help doctors choose safer, more effective dosing for kids.
This study monitors how the antifungal drug isavuconazole works in children's bodies. It aims to find the right dose for treating serious fungal infections.
This trial tests a new inhaled medicine (caspofungin) added to standard treatment for Pneumocystis pneumonia, a serious lung infection. It may help fight the infection more effectively while you are already receiving oxygen and standard antibiotics.
Hear when a new Pharmacokinetics trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.